Defence Therapeutics Inc.
DTC.F·Frankfurt·Healthcare
0.2280+0.0480 (+26.67%)today
As of Nov 5, 9:39 AM CET · May be delayed up to 15 min · EUR
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.1800
Open0.1980
Day range0.19800.2280
52-week range0.17000.5940
Off day high0.00%
Off 52-week high−61.62%
Volume10.00K
Avg. volume (3M)16.27K
Market cap17.35M
EPS (TTM)-0.0700
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding76.11M
Short interest—
Earnings date—
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| DTC.F | EVAX | IMU.AX | BCTX | AIM | IMNN | |
|---|---|---|---|---|---|---|
| Market cap | 17.35M | 27.39M | 19.39M | 27.86M | 6.42M | 5.09M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -198.0 | -0.9 | -8.2 | -0.4 | -0.5 |
| Price/book | 7.8 | 2.6 | 1.6 | 1.7 | 0.6 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −64.14% | −52.56% | −91.04% | −67.55% | −90.12% | −77.02% |
| Today | +26.67% | +0.34% | +16.67% | +5.98% | +0.19% | +0.78% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All DTC.F news ›Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Defence Therapeutics (DTCFF) won the Best Poster Award for its Accum research at World ADC San Diego 2026, held October 12–15. Defence Therapeutics (DTCFF) won the Best Poster Award for its Accum research at World ADC San Diego 2026, held…
From the 4Search news index, newest first.
In the news
2mentions in 30 days
2with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
- newsfilecorp.com1
- stocktitan.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.